Home › Research › Treatments
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)
Costa N, Mounié M, Pagès A, Derumeaux H, Rapp T, Guyonnet S, Coley N, Cantet C et al.. The journal of prevention of Alzheimer's disease, 2021-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background To date, no curative treatment is available for Alzheimer's disease (AD). Therefore, efforts should focus on prevention strategies to improve the efficiency of healthcare systems. Objective Our aim was to assess the cost-effectiveness of three preventive strategies for AD compared to a placebo. Design The Multidomain Alzheimer Preventive Trial (MAPT) study was a multicenter, randomized, placebo-controlled superiority trial with four parallel groups, including three intervention groups (one group with Multidomain Intervention (MI) plus a placebo, one group with Polyunsaturated Fatty Acids (PFA), one group with a combination of PFA and MI) and one placebo group. Setting Participants were recruited and included in 13 memory centers in France and Monaco. Participants Community-dwelling subject aged 70 years and older were followed during 3 years. Interventions We used data from the MAPT study which aims to test the efficacy of a MI along PFA, the MI plus a placebo, PFA alone, or a placebo alone. Measurement Direct medical and non-medical costs were calculated from a payer's perspective during the 3 years of follow-up. The base case incremental Cost-Effectiveness Ratio (ICER) represents the cost per improved cognitive Z-score point. Sensitivity analyses were performed using different interpretation of the effectiveness criteria. Results Analyses were conducted on 1,525 participants. The ICER at year 3 that compares the MI + PFA and the MI alone to the placebo amounted to €21,443 and €21,543 respectively, per improved Z score point. PFA alone amounted to €111,720 per improved Z score point. Conclusion Our study shows that ICERS of PFA combined with MI and MI alone amounted to €21,443 and €21,543 respectively per improved Z score point compared to the placebo and are below the WTP of €50,000 while the ICER of PFA alone amounted to €111,720 per improved Z score point. This information may help decision makers and serve as a basis for the implementation of a lifetime decision analytic model.
What this study adds
Evidence grade: High
The record lists 1,525 participants. This cost-effectiveness analysis of the MAPT prevention trial found that a multidomain intervention alone and combined with omega-3 fell below the willingness-to-pay threshold, while omega-3 alone did not. It addresses the economics of prevention strategies, not whether any strategy cures Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Costa, N., Mounié, M., Pagès, A., Derumeaux, H., Rapp, T., Guyonnet, S., et al. (2021). The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT). The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2021.47
Vancouver
Costa N, Mounié M, Pagès A, Derumeaux H, Rapp T, Guyonnet S, et al. The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT). The journal of prevention of Alzheimer's disease. 2021. doi:10.14283/jpad.2021.47. PMID: 34585216.
BibTeX
@article{costa2021-34585216,
author = {Costa, N. and Mounié, M. and Pagès, A. and Derumeaux, H. and Rapp, T. and Guyonnet, S. and Coley, N. and Cantet, C. and others},
title = {{The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)}},
journal = {The journal of prevention of Alzheimer's disease},
year = {2021},
doi = {10.14283/jpad.2021.47},
pmid = {34585216},
url = {https://doi.org/10.14283/jpad.2021.47}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objective Our aim was to assess the cost-effectiveness of three preventive strategies for AD compared to a placebo.
- Results Analyses were conducted on 1,525 participants.
- Conclusion Our study shows that ICERS of PFA combined with MI and MI alone amounted to €21,443 and €21,543 respectively per improved Z score point compared to the placebo and are below the WTP of €50,000 while the ICER of PFA alone amounted to €111,720 per improved Z score point.
Why it matters
This cost-effectiveness analysis of the MAPT prevention trial found that a multidomain intervention alone and combined with omega-3 fell below the willingness-to-pay threshold, while omega-3 alone did not. It addresses the economics of prevention strategies, not whether any strategy cures Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants1,525
- Evidence strengthHigh
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The journal of prevention of Alzheimer's disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,525 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 2 / 6 | Cited 1.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Laurent Molinier: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34585216) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.14283/jpad.2021.47
- PubMed: 34585216
- Original source →
- Free full text: The Journal of Prevention of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also in Treatments
194 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.